Supply Chain Intelligence

Edgewise Therapeutics, Inc. Supply Chain

EWTX supply chain intelligence for Edgewise Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

EWTX ·Last updated 2026-07-29 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

2Suppliers
4Customers
2Debt Items
16Related Chains

Edgewise Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
SANTHERA SANTHERA 80% Catalyst Pharmaceuticals, Inc. has commercialized this product in the United States following its North America exclusive license deal with Santhera.
KROS Keros Therapeutics, Inc. 72% Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirement…

Edgewise Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
CATALYST-PHARMACEUTICALS-INC CATALYST-PHARMACEUTICALS-INC 85% In October 2023, the FDA granted AGAMREE (vamorolone) approval in Duchenne patients aged 2 years and older and Catalyst Pharmaceuticals, Inc. has commercialized this product in the United States foll…
NIPPON-SHINYAKU-CO-LTD NIPPON-SHINYAKU-CO-LTD 85% VILTEPSO (vitolarsen), a naked PMO approved for the treatment of Duchenne patients amenable to Exon 53 skipping, which is marketed by Nippon Shinyaku Co. Ltd.
SAREPTA-THERAPEUTICS-INC SAREPTA-THERAPEUTICS-INC 85% EXONDYS 51 (eteplirsen), AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen), which are naked phosphorodiamidate morpholino oligomers (PMOs) approved for the treatment of Duchenne patients amenable t…
KROS Keros Therapeutics, Inc. 72% Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirement…

Edgewise Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
EWTX-DEBT-9407 Xbrl Convertible 90% xbrl convertible detail from xbrl 2021-12-31.
EWTX-DEBT Debt stack $3.8M 90% Market cache reports total debt of $3.8M.

Edgewise Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Edgewise Therapeutics, Inc..

Edgewise Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
EWTX-OWNER-ORBIMED-ADVISORS-LLC ORBIMED ADVISORS LLC 90% 13F overlay lists ORBIMED ADVISORS LLC as top holder; 218 tracked holders.

Edgewise Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
REGN Regeneron Pharmaceuticals, Inc. 100.00 2
BMY Bristol-Myers Squibb Company 100.00 2
BMYMP Bristol-Myers Squibb Co 100.00 2
SNYNF Sanofi 100.00 2
TAK Takeda Pharmaceutical Company Limited 100.00 2
RNAM Avidity Biosciences, Inc. 100.00 2
MSLE Satellos Bioscience Inc. 100.00 2
IBIO iBio, Inc. 100.00 2
TKPHF Takeda Pharmaceutical Company Limited 100.00 2
MYGN Myriad Genetics, Inc. 100.00 2
SRPT Sarepta Therapeutics, Inc. 100.00 2
SRRK Scholar Rock Holding Corporation 100.00 2
KROS Keros Therapeutics, Inc. 36.29 1 ['customer', 'supplier']
GOSS Gossamer Bio, Inc. 14.78 2
PTCT PTC Therapeutics, Inc. 14.78 2
SLDB Solid Biosciences Inc. 14.78 2
View EWTX supply chain intel →

Explore the full interactive supply chain map for Edgewise Therapeutics, Inc..

Open EWTX supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map